Inhaled prostacyclin for Eisenmenger syndrome complicated with miliary tuberculosis
Keywords:
inhaled prostacyclin, Eisenmenger syndrome, miliary tuberculosis
Abstract
Eisenmenger syndrome occurs in patients with large congenital cardiac or extracardiac left-to-right shunts. Clinically, Eisenmenger syndrome is characterized by multiple organ involvement and progressive deterioration of function over time. In the advanced stages, signs and symptoms of Eisenmenger syndrome include central cyanosis, dyspnea, fatigue, hemoptysis, syncope and right-sided heart failure. Survival of patients with Eisenmenger syndrome is generally poor, but appears to be better than that of patients with idiopathic pulmonary arterial hypertension (PAH) in a comparable functional class.1References
1. Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome. Drugs. 2008;68;1049-66.
2. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:332-9.
3. Olschweski H, Ghofrani A, Schmehl T, Winkler J, Wilkens H, Hoper MM, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med. 2000;132:435-43.
4. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetther E, Niedermeyer J, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-70.
5. B Beghetti M, Berner M, Rimensberger PC. Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart 2001;86:e10.
6. Beghetti M, Nicod L, Barazzone-Argiroffo C, Rimensberger PC. New combined treatments avoid transplantation in a child with severe pulmonary hypertension. Heart. 2004;90:154.
7. Emmel M, Keuth B, Schickendantz S. Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost. Heart. 2003;90:e2.
8. R Rimensberger PC, Spahr-Schophfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation. 2001;103:544-8.
9. Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol. 2003;92:1007-9.
2. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:332-9.
3. Olschweski H, Ghofrani A, Schmehl T, Winkler J, Wilkens H, Hoper MM, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med. 2000;132:435-43.
4. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetther E, Niedermeyer J, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-70.
5. B Beghetti M, Berner M, Rimensberger PC. Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart 2001;86:e10.
6. Beghetti M, Nicod L, Barazzone-Argiroffo C, Rimensberger PC. New combined treatments avoid transplantation in a child with severe pulmonary hypertension. Heart. 2004;90:154.
7. Emmel M, Keuth B, Schickendantz S. Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost. Heart. 2003;90:e2.
8. R Rimensberger PC, Spahr-Schophfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation. 2001;103:544-8.
9. Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol. 2003;92:1007-9.
Published
2011-08-30
How to Cite
1.
Marwali E, Budiwardhana N, Rahayoe A. Inhaled prostacyclin for Eisenmenger syndrome complicated with miliary tuberculosis. PI [Internet]. 30Aug.2011 [cited 25Nov.2024];51(4):241-. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/877
Section
Case Report
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Received 2016-10-12
Accepted 2016-10-12
Published 2011-08-30
Accepted 2016-10-12
Published 2011-08-30
